Semax is a peptide studied in neurological research, including rehabilitation after stroke. Its evidence should be read in the context of the participants and outcomes studied, rather than as a general promise of better concentration or brain recovery.
What the research shows
A 2018 study of 110 post-stroke patients reported BDNF and daily-function changes during rehabilitation. A 2020 healthy-volunteer study examined functional brain connectivity. These findings do not establish a general cognitive-enhancement benefit. [1] [2] [3]
Related substances appeared on the FDA’s 2026 compounding agenda; this is not product approval. [3]
Distinguishing substances and products
Semax and Selank are different substances. Comparisons with Cerebrolysin also require matching product evidence and study settings; a shared neurological theme is not a basis for ranking efficacy.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Has Semax been studied in people?
Yes, in post-stroke patients and volunteers, with different outcomes assessed.
Does Semax guarantee better concentration?
The cited studies do not support that guarantee for the general population or every product.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.